CN Patent
CN113278023B — 含氮杂环化合物及其制备方法和应用
Assigned to Shanghai Ruiyue Biotechnology Co ltd · Expires 2021-10-15 · 5y expired
What this patent protects
本发明涉及含氮杂环化合物及其制备方法和应用,该化合物具有式( )所示结构: 该化合物对人急性髓细胞白血病细胞具有较优的抑制活性,具有治疗相关疾病的潜能。且该化合物能够通过招募CRBN或VHL E3连接酶可以有效降解KIT蛋白,并抑制携带KIT突变细胞的生长和存活,故还具有治疗与KIT蛋白相关的疾病的潜能。
USPTO Abstract
本发明涉及含氮杂环化合物及其制备方法和应用,该化合物具有式( )所示结构: 该化合物对人急性髓细胞白血病细胞具有较优的抑制活性,具有治疗相关疾病的潜能。且该化合物能够通过招募CRBN或VHL E3连接酶可以有效降解KIT蛋白,并抑制携带KIT突变细胞的生长和存活,故还具有治疗与KIT蛋白相关的疾病的潜能。
Drugs covered by this patent
- Ayvakit (AVAPRITINIB) · Blueprint Medicines
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.